| Literature DB >> 32435567 |
Spogmai Zadran1, Peter Heide Pedersen1, Søren Eiskjær1.
Abstract
STUDYEntities:
Keywords: osteomyelitis; spondylodiscitis; statistical models; survival analysis
Year: 2019 PMID: 32435567 PMCID: PMC7222680 DOI: 10.1177/2192568219862213
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Figure 1.Flowchart for the 125 patients eligible for the study.
Variables, Coding, and Distribution According to Treatment.
| Variable Name and Coding | Conservative (0), n (%) | Surgery (1), n (%) | Total, n (%) |
|
|---|---|---|---|---|
| Male (0) | 36 (72) | 53 (71) | 89 (71) | 1 |
| Female (1) | 14 (28) | 22 (29) | 36 (29) | |
| Age >60 years (1) | 37 (74) | 55 (73) | 92 (74) | 1 |
| Age ≤60 years (0) | 13 (26) | 20 (27) | 33 (26) | |
| Diabetes (1) | 6 (12) | 17 (23) | 23 (18) | .2 |
| No diabetes (0) | 44 (88) | 58 (77) | 102 (87) | |
| Cardiovascular disease (1) | 16 (32) | 25 (33) | 41 (33) | 1 |
| No cardiovascular disease (0) | 34 (68) | 50 (67) | 84 (67) | |
| Lung disease (1) | 5 (10) | 6 (8) | 11 (9) | .95 |
| No lung disease (0) | 45 (90) | 69 (92) | 114 (91) | |
| Cancer (1) | 6 (12) | 12 (16) | 18 (14) | .72 |
| No cancer (1) | 44 (88) | 63 (84) | 107 (86) | |
| Renal disease (1) | 3 (6) | 7 (9) | 10 (8) | .74 |
| No renal disease (0) | 47 (94) | 68 (91) | 115 (92) | |
| Intravenous drug abuser (1) | 0 (0) | 8 (11) | 8 (6) | .04 |
| Not an intravenous drug abuser (0) | 50 (100) | 67 (89) | 117 (94) | |
| Alcoholic (1) | 9 (18) | 11 (15) | 20 (16) | .8 |
| Not an alcoholic (0) | 41 (82) | 64 (85) | 105 (84) | |
| Charlson Comorbidity Index > 1 (1) | 23 (46) | 45 (60) | 57 (46) | .18 |
| Charlson Comorbidity Index ≤ 1 (0) | 27 (54) | 30 (40) | 68 (54) | |
| Frankel grade not E (1) | 19 (38) | 33 (44) | 52 (42) | .63 |
| Frankel grade E (0) | 31 (62) | 42 (56) | 73 (59) | |
| Karnofsky score <80 (1) | 24 (48) | 32 (43) | 56 (45) | .68 |
| Karnofsky score ≥80 (0) | 26 (52) | 43 (57) | 69 (55) | |
| Endocarditis (1) | 8 (16) | 10 (13) | 18 (14) | .88 |
| No endocarditis (0) | 42 (84) | 65 (87) | 107 (86) | |
| Paravertebral or epidural abscess (1) | 13 (26) | 48 (64) | 61 (49) | .00007 |
| No abscess (0) | 37 (74) | 27 (36) | 64 (51) | |
| Vertebral body destruction (1) | 2 (4) | 11 (15) | 13 (10) | .11 |
| No vertebral body destruction (0) | 48 (96) | 64 (85) | 112 (90) | |
| Thoracic spine infection (1) | 13 (26) | 22 (29) | 35 (28) | .84 |
| Not thoracic spine infection (0) | 37 (74) | 53 (71) | 90 (72) | |
| 17 (34) | 24 (32) | 41 (33) | .97 | |
| No | 33 (66) | 51 (68) | 84 (67) | |
| C-reactive protein ≤30 mg/L 14 days after treatment start (0) | 32 (64) | 28 (37) | 60 (48) | .006 |
| C-reactive protein >30 mg/L 14 days after treatment start (1) | 18 (36) | 47 (63) | 65 (52) |
Figure 2.Overall survival for the 125 patients. Blue area indicates 95% confidence limits.
Conventional Univariate Cox Regression Analysis.
| Variable | Hazard Ratio | 95% CI |
|
|---|---|---|---|
| Sex | 1.31 | 0.53-3.26 | .56 |
| Age | 2.28 | 0.67-7.73 | .14 |
| Treatment | 1.73 | 0.67-4.46 | .24 |
| Diabetes | 1.93 | 0.75-4.96 | .20 |
| Cardiovascular disease | 2.93 | 1.23-6.95 | .015 |
| Lung disease | 0.5 | 0.07-3.75 | .45 |
| Cancer | 1.45 | 0.49-4.32 | .52 |
| Renal disease | 3.19 | 1.07-9.48 | .07 |
| Intravenous drug abuse | 0.71 | 0.10-5.29 | .72 |
| Alcoholic | 1.34 | 0.45-3.99 | .61 |
| Charlson Comorbidity Index | 3.98 | 1.34-11.85 | .005 |
| Frankel grade | 1.64 | 0.70-3.86 | .26 |
| Karnofski score | 1.79 | 0.75-4.24 | .19 |
| Endocarditis | 1 | 0.29-3.40 | .99 |
| Paravertebral or epidural abscess | 0.93 | 0.39-2.18 | .86 |
| Vertebral body destruction | 1.47 | 0.43-4.99 | .55 |
| Thoracic spine infection | 2.12 | 0.89-5.04 | .09 |
|
| 1.03 | 0.42-2.56 | .94 |
| C-reactive protein ≤30 mg/L 14 days after treatment start | 3.28 | 1.20-8.96 | .01 |
Figure 3.Kaplan Meier curves comparing conservative treatment and surgery. Vertical lines indicate 95% confidence intervals.
Figure 4.Maximum lambda1.
Figure 5.Path of the standardized coefficient estimates over a range of values of the LASSO constraint lambda1. The vertical gray line is the optimal value of lambda, the same value as in Figure 4.
Nonzero Coefficients From the LASSO Penalized Cox Proportional Hazard Regression.
| Variable | Coefficient |
|---|---|
| Charlson Comorbidity Index | 0.55 |
| C-reactive protein normalization | 0.45 |
| Cardiovascular disease | 0.30 |
| Thoracic spine infection | 0.18 |
| Karnofsky score | 0.07 |
Figure 6.Predicted survival profiles for patients 24 and 55.
Figure 7.Time-dependent AUC (area under the receiver operating characteristic [ROC] curve) for the LASSO model. Solid line indicates mean of the AUC and dashed line indicates the median of the AUC. Darker interval indicates 25% and 75% quantiles of AUC. Lighter interval indicate minimum and maximum of AUC.